Q2 Solutions

Q2 Solutions provides a comprehensive set of flexible solutions tailored for small and mid-sized biotech companies. The company offers Central Laboratory Services, including flow cytometry, anatomic pathology, molecular and companion diagnostics, and decentralized clinical trials. Q2 Solutions specializes in ADME, bioanalytical, genomics, immunoassay testing, vaccines, and antibody drug discovery. The company has a dedicated Digital Innovation department focused on driving operational improvements and enhancing the quality of services. Additionally, Q2 Solutions operates a Translational Science and Innovation Laboratory (TSAIL) for early biomarker evaluation and provides specialized biomarkers in various domains such as anatomic pathology, flow cytometry, immunoassays, molecular, genomics, CDx, and PK/ADME. The company supports therapeutic areas including oncology, gastroenterology, neuroscience, and vaccines. With a global presence spanning North America, Europe, South America, Asia, and Africa, Q2 Solutions operates under harmonized workflows and Standard Operating Procedures (SOPs) across its locations, including China. The company offers dedicated project leadership and executive sponsorship to support clinical trials from initiation through execution. Q2 Solutions provides immunoassay solutions with platforms like SpectraMax Plate Reader, AushonCira-Scan, Luminex, Mesoscale Discovery, Quanterix SiMoA, and Protein Simple Ella, and maintains a broad soluble biomarker portfolio covering single analyte, multiplex, high sensitivity, and fully automated assays. The company also offers specialized services through sub-brands such as BioFortis, Nexelis, ImmunXperts, Rules-Based Medicine, and Specifica. Q2 Solutions provides end-to-end laboratory services aligned to support various therapeutic areas and has a dedicated team of researchers and scientists continuously striving to develop pioneering solutions in drug discovery and development laboratory services.